Literature DB >> 2553864

Adrenergic receptors in aging and Alzheimer's disease: increased beta 2-receptors in prefrontal cortex and hippocampus.

R N Kalaria1, A C Andorn, M Tabaton, P J Whitehouse, S I Harik, J R Unnerstall.   

Abstract

Loss of pigmented noradrenergic locus ceruleus neurons occurs in Alzheimer's disease (AD) and, to a lesser extent, in aging. We studied beta-adrenergic receptors and their subtypes, beta 1 and beta 2, by the specific binding of 125I-pindolol to particulate membrane preparations from prefrontal cortex, hippocampus, putamen, and cerebellum and to sections from frontal cortex by in vitro autoradiography. In prefrontal cortex from controls, numbers of total beta- and beta 2-adrenoceptors did not significantly correlate with age, but number of beta 1-adrenoceptors showed a weak but significant negative correlation. Binding in tissue particulate preparations to total beta-receptors did not reveal significant differences in samples from prefrontal cortex between AD subjects and age-matched controls. However, beta 1-adrenoceptors were decreased and beta 2-adrenoceptors were increased in number by approximately 30-50% in AD subjects. Thus, the relative ratio of beta 1-/beta 2-receptors was decreased in AD. Binding by in vitro receptor autoradiography performed in a subset of samples of frontal cortex also showed beta 2-adrenoceptors, and less consistently total beta- and beta 1-receptors, to be increased significantly in number in cortical laminae II, III, IV, and V of tissue sections from AD subjects. In these subjects, number of locus ceruleus cells and norepinephrine concentrations in putamen and frontal cortex were markedly reduced compared with values in controls. In the hippocampus, total beta- and both beta 2- and beta 1-adrenoceptors were increased in number in AD. In contrast, in the putamen, where beta 1-receptors predominate, total beta- and beta 1-receptors were significantly decreased in number with no consistent change in content of beta 2-receptors in AD. There were no significant changes in the cerebellum. Specific pindolol binding was not affected by interval between death and sampling of tissue at autopsy. Our results indicate selective changes in number of beta-receptors in AD. These changes in the cortex and hippocampus suggest receptor upregulation in response to noradrenergic deafferentation from the locus ceruleus or may simply reflect glial proliferation in AD.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2553864     DOI: 10.1111/j.1471-4159.1989.tb09242.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  43 in total

Review 1.  Amyloid beta peptide membrane perturbation is the basis for its biological effects.

Authors:  J N Kanfer; G Sorrentino; D S Sitar
Journal:  Neurochem Res       Date:  1999-12       Impact factor: 3.996

2.  Modulation of neuroinflammation and pathology in the 5XFAD mouse model of Alzheimer's disease using a biased and selective beta-1 adrenergic receptor partial agonist.

Authors:  Pooneh Memar Ardestani; Andrew K Evans; Bitna Yi; Tiffany Nguyen; Laurence Coutellier; Mehrdad Shamloo
Journal:  Neuropharmacology       Date:  2017-01-13       Impact factor: 5.250

3.  Distribution of the beta-2 adrenergic receptor messenger RNA in the rat brain by in situ hybridization histochemistry: effects of chronic reserpine treatment.

Authors:  M Asanuma; N Ogawa; K Mizukawa; K Haba; H Hirata; A Mori
Journal:  Neurochem Res       Date:  1991-12       Impact factor: 3.996

4.  Adrenergic receptors in Alzheimer's disease brain: selective increases in the cerebella of aggressive patients.

Authors:  A Russo-Neustadt; C W Cotman
Journal:  J Neurosci       Date:  1997-07-15       Impact factor: 6.167

Review 5.  The basis for behavioural disturbances in dementia.

Authors:  M M Esiri
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-08       Impact factor: 10.154

6.  Basal forebrain cholinergic immunolesion by 192IgG-saporin: evidence for a presynaptic location of subpopulations of alpha 2- and beta-adrenergic as well as 5-HT2A receptors on cortical cholinergic terminals.

Authors:  M Heider; R Schliebs; S Rossner; V Bigl
Journal:  Neurochem Res       Date:  1997-08       Impact factor: 3.996

Review 7.  Beta-adrenergic function in aging. Basic mechanisms and clinical implications.

Authors:  P J Scarpace; N Tumer; S L Mader
Journal:  Drugs Aging       Date:  1991-03       Impact factor: 3.923

Review 8.  Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.

Authors:  Yunqi Xu; Junqiang Yan; Peng Zhou; Jiejie Li; Huimin Gao; Ying Xia; Qing Wang
Journal:  Prog Neurobiol       Date:  2012-02-25       Impact factor: 11.685

Review 9.  Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights.

Authors:  Dharmini C Mehta; Jennifer L Short; Sarah N Hilmer; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2014-10-16       Impact factor: 4.200

10.  Profiling of Differential Expression of Genes in Mice Carrying Both Mutant Presenilin 1 and Amyloid Precursor Protein Transgenes with or without Knockout of B2 Adrenergic Receptor Gene.

Authors:  Yuan Zhou; Lintao Chen; Xi Zhou; Yechun Pei; Shuangshuang Wei; Anum Mehmood; Yang K Xiang; Dayong Wang
Journal:  J Appl Bioinforma Comput Biol       Date:  2018-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.